Pure Global

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women - Trial NCT05930704

Access comprehensive clinical trial information for NCT05930704 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Recruiting. The study focuses on Osteoporosis. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05930704
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05930704
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection Administered Subcutaneously to Postmenopausal Women

Study Focus

Osteoporosis

SHR-2017 injection

Interventional

drug

Sponsor & Location

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Jinan, China

Timeline & Enrollment

Phase 1

Jul 04, 2023

Apr 12, 2025

45 participants

Primary Outcome

Number of participants with adverse events

Summary

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single
 subcutaneous (SC) injection in postmenopausal women

ICD-10 Classifications

Osteoporosis, unspecified
Other osteoporosis
Idiopathic osteoporosis
Osteoporosis in diseases classified elsewhere
Postmenopausal osteoporosis

Data Source

ClinicalTrials.gov

NCT05930704

Non-Device Trial